Clinical trials: Tumor Markers, Biological
Gastrointestinal Disease, Esophageal Cancer
FDG-PET-CT and Biomarkers in Esophageal Cancer
The goal of this clinical research study is to learn if the results of a positron emission tomography/computed tomography (PET/CT) scan done 10-14 days after beginning chemotherapy and radiation (chemoradiation) can predict how a…
- Trial name
- NCT00833625
- Testing
- PET/CT (FDG PET/CT), Biomarker Testings
- Where
- United States
- Volunteers
- 31 people
- Sponsor
- M.D. Anderson Cancer Center
Hemangioma
A Prospective Longitudinal Study to Identify Biomarkers in Children With Hemangiomas
Current treatment options for hemangiomas, such as propranolol, steroids and interferon, all have the potential for significantly harmful side effects.
- Trial name
- NCT01598116
- Testing
- Urine collection and ultrasonography, Urine collection
- Where
- United States
- Volunteers
- 68 people, healthy volunteers welcome
- Sponsor
- Gayle Gordillo
Biomarker Change Linked to Breast Cancer
Changes in Biomarkers Using Prostaglandin Inhibitors
This is a biomarker study with the goal of measuring changes in proteins and gene methylation. This study is not intended for use in diagnosing, mitigating, treating, curing, or preventing disease.
- Trial name
- NCT01769625
- Where
- United States
- Volunteers
- 31 people, healthy volunteers welcome
- Sponsor
- Hartford Hospital
Prostate Cancer, Prostate Adenocarcinoma
ARCTIC: Liquid Biomarkers in the Prospective Androgen Receptor Signaling Inhibitors (ARSI) Resistance Clinical Trials
This study will follow men with metastatic castration resistant prostate cancer throughout their standard of care treatment for their disease to determine if the presence of different genes or proteins can predict which patients…
- Conditions
- Prostate Cancer, Prostate Adenocarcinoma, Prostate Cancer Metastatic, Castration-resistant Prostate Cancer
- Trial name
- ARCTIC (NCT06141993)
- Where
- 3 sites in United States
- Volunteers
- 120 people
- Sponsor
- Duke University
Esophageal Neoplasm, Esophageal Neoplasms Malignancy Unspecified
Measuring Cell Free DNA During the Course of Treatment for Esophageal Cancer as a Marker of Response and Recurrence
To prospectively collect blood and tumor tissue from esophageal cancer patients to identify specific esophageal cancer mutations that can be measured in the blood (cell free DNA) during the course of treatment as a marker of…
- Conditions
- Esophageal Neoplasm, Esophageal Neoplasms Malignancy Unspecified, Esophageal Neoplasms Malignant, Cancer of Esophagus
- Trial name
- NCT03108885
- Testing
- Blood and Tissue Collection
- Where
- United States
- Volunteers
- 11 people
- Sponsor
- Mayo Clinic
Breast Cancer Prevention, Mammographic Density
RANKL Inhibition and Breast Tissue Biomarkers
A robust knowledge of how to reduce breast density could play a key role in breast cancer prevention in premenopausal women, but viable preventative targets to reduce breast density-associated breast cancer risk are yet to be…
- Trial name
- NCT03629717
- Testing
- Ultrasound-guided core needle biopsy, Denosumab, Blood draw
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- Washington University School of Medicine
Epithelial Ovarian Cancer
Tinzaparin And Biomarkers After Neoadjuvant Treatment of Ovarian Cancer
Background: Previous findings have indicated antineoplastic properties of tinzaparin (Innohep®), a commonly used anti-coagulant.
- Trial name
- NCT05284552
- Testing
- Tinzaparin Injectable Solution
- Where
- 8 sites in Sweden
- Volunteers
- 40 people
- Sponsor
- University Hospital, Linkoeping
Ovarian Neoplasms, Breast Neoplasms
Establishment of a Tumor Bank for Blood Samples
Establishment of a tumor bank, consisting of blood samples of tumor patients and healthy people as controls. The blood samples will be collected systematically together with the corresponding clinical data.
- Conditions
- Ovarian Neoplasms, Breast Neoplasms, Colorectal Neoplasms, Neoplasms of the Female Genitalia
- Trial name
- NCT01763125
- Testing
- Blood collection
- Where
- 6 sites in Austria, Belgium and 2 more
- Volunteers
- 10,000 people, healthy volunteers welcome
- Sponsor
- Medical University of Vienna
Ovarian Cancer, Clinical Marker
The Clinical Markers for PARP Inhibitors-related Efficacy in Ovarian Cancer
Epithelial ovarian cancer (EOC) is the most lethal gynecological malignancy. PARP inhibitors(PARPi) are an important progress in EOC treatment.
- Conditions
- Ovarian Cancer, Clinical Marker, PARP Inhibitor
- Trial name
- ROMP (NCT04582552)
- Testing
- PARP inhibitors
- Where
- China
- Volunteers
- 60 people
- Sponsor
- Xiaoxiang Chen
Colorectal Cancer, Metastatic Colorectal Adenocarcinoma
Dual-Targeting CAR-NK Cells in Biomarker-Selected Advanced Colorectal Cancer
This Phase 1/2 study evaluates the safety, tolerability, and preliminary anti-tumor activity of an allogeneic dual-target chimeric antigen receptor natural killer (CAR-NK) cell product in adults with advanced or metastatic…
- Conditions
- Colorectal Cancer, Metastatic Colorectal Adenocarcinoma, Unresectable Colorectal Cancer
- Trial name
- DUO-CRC-NK-111 (NCT07589517)
- Testing
- EB-DUO-CAR-NK-CEA/GCC, Lymphodepletion
- Where
- China
- Volunteers
- 48 people
- Sponsor
- Beijing Biotech
Leukemia
RNA Biomarkers in Tissue Samples From Infants With Acute Myeloid Leukemia
RATIONALE: Studying samples of tissue from patients with cancer in the laboratory may help doctors learn more about changes that occur in RNA and identify biomarkers related to cancer.
- Trial name
- NCT01229124
- Testing
- RNA analysis, nucleic acid sequencing, reverse transcriptase-polymerase chain reaction
- Volunteers
- 20 people
- Sponsor
- Children's Oncology Group
Head and Neck Cancer, Chronic Periodontitis
Estimation of (suPAR) in Chronic Periodontitis With Post-radiotherapy on HNCs Patients
This study aims to improve a soluble urokinase plasminogen activator receptor suPAR is a reliable biomarker of chronic periodontitis and may be replaced in patients with head and neck cancer post-radiotherapy (HNC post-RT).
- Conditions
- Head and Neck Cancer, Chronic Periodontitis, Radiotherapy Side Effect
- Trial name
- HNCs (NCT06529588)
- Testing
- Radiation
- Where
- Iraq
- Volunteers
- 150 people, healthy volunteers welcome
- Sponsor
- Al-Maarif University College
Breast Neoplasms, Breast Cancer
Assessment of Breast Cancer Response to Neoadjuvant Anthracycline-based Chemotherapy by FDG-PET and Molecular Markers
A correlation between early changes in the tumor maximum standardized uptake value (SUVmax) on FDG-PET after one or two cycles of neoadjuvant chemotherapy (NAC) and the pathological response after 6 to 8 cycles has been…
- Trial name
- NCT02600442
- Testing
- non interventional study
- Where
- France
- Volunteers
- 168 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Mantle Cell Lymphoma, Chronic Lymphocytic Leukaemia
Tissue Collection for Biomarkers Determining Resistance to Ibrutinib
Clinical validation of biomarkers determining resistance to BTK inhibition with Ibrutinib in Mantle Cell Lymphoma and Chronic Lymphocytic Leukaemia Stage 1.
- Trial name
- CLARITY (NCT02267590)
- Where
- United Kingdom
- Volunteers
- 120 people
- Sponsor
- Royal Marsden NHS Foundation Trust
Breast Cancer
S9313B Study of Tumor Tissue Samples From Women With Early-Stage Breast Cancer Enrolled on Clinical Trial SWOG-9313
RATIONALE: Studying samples of tumor tissue from patients with cancer in the laboratory may help doctors learn more about changes that occur in DNA and identify biomarkers related to cancer.
- Trial name
- NCT00949013
- Testing
- immunohistochemistry staining method, laboratory biomarker analysis
- Volunteers
- 1,600 people
- Sponsor
- SWOG Cancer Research Network
Advanced Prostate Cancer, Cabazitaxel
PROSTAC: Prospective Multi-centre Study of Prognostic Factors in mCRPC Patients Treated With Docetaxel or Cabazitaxel.
PROSTAC is a prospective multicentre observational study in metastatic Castration-Resistant Prostate Cancer (mCRPC), designed to explore prognostic biomarkers in patients undergoing treatment with docetaxel or cabazitaxel
- Conditions
- Advanced Prostate Cancer, Cabazitaxel, Docetaxel
- Trial name
- PROSTAC (NCT02362620)
- Where
- 25 sites in Spain
- Volunteers
- 402 people
- Sponsor
- Centro Nacional de Investigaciones Oncologicas CARLOS III
Non-small Cell Lung Cancer, Metastatic Non Small Cell Lung Cancer
A Study of Local Ablative Therapy (LAT) in People With Non-Small Cell Lung Cancer (NSCLC)
The purpose of this study is to see whether receiving local ablative therapy (LAT) when minimal residual disease/MRD levels are rising can reduce MRD levels and control metastatic non-small cell lung cancer/NSCLC longer compared…
- Conditions
- Non-small Cell Lung Cancer, Metastatic Non Small Cell Lung Cancer, Nsclc, NSCLC Stage IV
- Trial name
- NCT05429320
- Testing
- Local ablative therapy, Blood collection to assess for ctDNA
- Where
- 9 sites in United States
- Volunteers
- 37 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Glioblastoma
Cytochrome C Oxidase Activity in Newly Diagnosed Glioblastoma Multiforme (GBM)
This is a multi-institutional, consortium-based, non-interventional prospective blinded endpoints clinical study to determine whether high activity of Cytochrome C Oxidase (CcO) in tumor specimens from subjects with newly…
- Trial name
- NCT02997423
- Where
- 19 sites in United States
- Volunteers
- 153 people
- Sponsor
- University of Iowa
Prostate Cancer, Metastatic Prostate Adenocarcinoma
Tumor Molecular Profiling in Patients With Prostate Cancer
The aim of the study was to evaluate the prevalence, the prognostic and predictive value of gene alterations in unselected patients with prostate cancer.
- Trial name
- NCT05573789
- Testing
- Tumor molecular profiling
- Where
- Greece
- Volunteers
- 220 people
- Sponsor
- Hellenic Cooperative Oncology Group
Cardiovascular Diseases, Cancer
Phase I Human Analytics (HALO) Study
Discover, optimize, standardize, and validate clinical-trial measures and biomarkers used to diagnose and differentiate cardiovascular, oncologic, neurologic, and other diseases and disorders.
- Conditions
- Cardiovascular Diseases, Cancer, Dementia, Traumatic Brain Injury
- Trial name
- HALO (NCT05423860)
- Testing
- no interventions will be performed (observational)
- Where
- United States
- Volunteers
- 2,000 people
- Sponsor
- HALO Diagnostics
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.